Legend Biotech Corp (LEGN) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US52490G1022
Legend Biotech Corp (NASDAQ: LEGN) is a clinical-stage biopharmaceutical company specializing in the development and production of innovative cell therapies for oncology and other medical indications globally.
The company's flagship product, LCAR-B38M, is a unique chimeric antigen receptor designed for treating multiple myeloma (MM), a specific form of cancer.
In addition to its primary product, Legend Biotech Corp features a diverse range of autologous CAR-T product candidates at various developmental stages. These potential therapies target a wide spectrum of cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
Established in 2014 and headquartered in Somerset, New Jersey, Legend Biotech Corp operates globally, with a strong presence in the United States and China.
Moreover, Legend Biotech Corp has entered into strategic collaboration and licensing agreements, such as the partnership with Janssen Biotech, Inc., focusing on the development and commercialization of ciltacabtagene autoleucel, further expanding its reach and impact in the field of biopharmaceuticals.
For more information on Legend Biotech Corp, visit their official website at https://www.legendbiotech.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
LEGN Stock Overview
| Market Cap in USD | 10,576m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2020-06-05 |
LEGN Stock Ratings
| Growth 5y | 2.20 |
| Fundamental | -5.25 |
| Dividend | - |
| Rel. Performance vs Sector | -1.16 |
| Analysts | 4.21/5 |
| Fair Price Momentum | 52.99 USD |
| Fair Price DCF | - |
LEGN Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
LEGN Growth Ratios
| Growth 12m | -21.87% |
| Growth Correlation 12m | -57% |
| Growth Correlation 3m | -17% |
| CAGR 5y | 7.42% |
| Sharpe Ratio 12m | -0.72 |
| Alpha vs SP500 12m | -43.55 |
| Beta vs SP500 5y weekly | 0.95 |
| ValueRay RSI | 2.03 |
| Volatility GJR Garch 1y | 46.71% |
| Price / SMA 50 | -18.51% |
| Price / SMA 200 | -23.42% |
| Current Volume | 1412k |
| Average Volume 20d | 1001.3k |
External Links for LEGN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 19, 2024, the stock is trading at USD 48.83 with a total of 1,411,963 shares traded.
Over the past week, the price has changed by -12.00%, over one month by -24.48%, over three months by -18.47% and over the past year by -10.81%.
According to ValueRays Forecast Model, LEGN Legend Biotech Corp will be worth about 59 in April 2025. The stock is currently trading at 48.83. This means that the stock has a potential upside of +20.79%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 86.6 | 77.3% |
| Analysts Target Price | 88.4 | 81.0% |
| ValueRay Target Price | 59 | 20.8% |